BullFrog AI Holdings Inc. (NASDAQ: BFRG) announced it has signed a commercial feasibility agreement with a top 5 global pharmaceutical company and completed financing activities to extend its operational runway into late 2027.

The agreement, announced March 30, involves using BullFrog AI's bfLEAP platform to identify drug targets for major depressive disorder, a market valued at more than $8 billion in 2025. The deal includes milestone payments and provides the pharmaceutical partner an option to secure exclusive rights to selected target candidates for research and development.

The company completed financing activities in late March through sales under its at-the-market and equity-line-of-credit facilities. BullFrog AI said it now has stockholders' equity exceeding $2.5 million, meeting Nasdaq's minimum listing requirements.

BullFrog AI launched bfARENAS in March 2026, completing what it describes as an integrated AI platform for pharmaceutical research and development. The platform includes bfPREP for data preparation, bfLEAP for drug target identification, and bfARENAS for portfolio and clinical trial design decisions.

The company's technology stems from research conducted at Johns Hopkins University Applied Physics Laboratory. Through collaboration with the Lieber Institute for Brain Development, BullFrog AI accesses a dataset of more than 2,800 human brain samples for neuropsychiatric research.

Chief Executive Vin Singh said in a shareholder letter that the company plans to expand its relationship with the top 5 pharmaceutical partner and advance discussions with other global pharmaceutical and biotechnology organizations. The company is also building scientific evidence to support enterprise-level commercial conversations.

BullFrog AI said its lean operating structure creates potential for significant leverage as commercial revenue scales, with individual partnerships potentially extending operational runway and reducing dilution risk.